BR112016004904A8 - moduladores de receptor x do fígado (lxr), composição farmacêutica, seus usos e método para modular atividade de lxr - Google Patents

moduladores de receptor x do fígado (lxr), composição farmacêutica, seus usos e método para modular atividade de lxr

Info

Publication number
BR112016004904A8
BR112016004904A8 BR112016004904A BR112016004904A BR112016004904A8 BR 112016004904 A8 BR112016004904 A8 BR 112016004904A8 BR 112016004904 A BR112016004904 A BR 112016004904A BR 112016004904 A BR112016004904 A BR 112016004904A BR 112016004904 A8 BR112016004904 A8 BR 112016004904A8
Authority
BR
Brazil
Prior art keywords
lxr
modulators
liver
receptor
pharmaceutical composition
Prior art date
Application number
BR112016004904A
Other languages
English (en)
Other versions
BR112016004904A2 (pt
BR112016004904B1 (pt
Inventor
Mohan Raju
Original Assignee
Alexar Therapeutics Inc
Ralexar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexar Therapeutics Inc, Ralexar Therapeutics Inc filed Critical Alexar Therapeutics Inc
Publication of BR112016004904A2 publication Critical patent/BR112016004904A2/pt
Publication of BR112016004904A8 publication Critical patent/BR112016004904A8/pt
Publication of BR112016004904B1 publication Critical patent/BR112016004904B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

MODULADORES DE RECEPTOR X DO FÍGADO (LXR). Aqui são descritos moduladores do receptor X do fígado (LXR) e métodos de utilizar moduladores LXR no tratamento de doenças, distúrbios ou condições associadas com LXR. Também aqui descritas são composições farmacêuticas contendo tais compostos.
BR112016004904-7A 2013-09-04 2014-09-04 Compostos moduladores de receptor x do fígado (lxr), seu uso e composição farmaceutica compreendendo os mesmos BR112016004904B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361873755P 2013-09-04 2013-09-04
US61/873,755 2013-09-04
PCT/US2014/054043 WO2015035015A1 (en) 2013-09-04 2014-09-04 Liver x receptor (lxr) modulators

Publications (3)

Publication Number Publication Date
BR112016004904A2 BR112016004904A2 (pt) 2017-08-01
BR112016004904A8 true BR112016004904A8 (pt) 2021-06-22
BR112016004904B1 BR112016004904B1 (pt) 2023-01-24

Family

ID=52628918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016004904-7A BR112016004904B1 (pt) 2013-09-04 2014-09-04 Compostos moduladores de receptor x do fígado (lxr), seu uso e composição farmaceutica compreendendo os mesmos

Country Status (23)

Country Link
US (7) US10047055B2 (pt)
EP (2) EP3041835B1 (pt)
JP (2) JP6806961B2 (pt)
KR (1) KR102281803B1 (pt)
CN (2) CN105658636B (pt)
AU (1) AU2014315280B2 (pt)
BR (1) BR112016004904B1 (pt)
CA (1) CA2923175C (pt)
CY (1) CY1124057T1 (pt)
DK (1) DK3041835T3 (pt)
ES (1) ES2804304T3 (pt)
HR (1) HRP20201054T1 (pt)
HU (1) HUE051094T2 (pt)
IL (1) IL244418B (pt)
LT (1) LT3041835T (pt)
MX (1) MX371343B (pt)
NZ (1) NZ717688A (pt)
PL (1) PL3041835T3 (pt)
PT (1) PT3041835T (pt)
RS (1) RS60479B1 (pt)
SG (1) SG11201601640SA (pt)
SI (1) SI3041835T1 (pt)
WO (1) WO2015035015A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040231T2 (hu) 2012-03-02 2019-02-28 Ralexar Therapeutics Inc Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére
LT3041835T (lt) 2013-09-04 2020-07-27 Ellora Therapeutics, Inc. Kepenų x receptoriaus (lxr) moduliatoriai
SG11201601644RA (en) 2013-09-04 2016-04-28 Alexar Therapeutics Inc Liver x receptor (lxr) modulators
CN110305141B (zh) * 2019-07-18 2022-01-11 深圳市三启药物开发有限公司 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353905A (en) * 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
WO2002024632A2 (en) 2000-09-18 2002-03-28 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1511723A1 (en) 2002-05-24 2005-03-09 Pharmacia Corporation Sulfone liver x-receptor modulators
JP2005527621A (ja) 2002-05-24 2005-09-15 ファーマシア コーポレイション アニリノ肝ｘ受容体調節因子
AU2003301020A1 (en) 2002-12-20 2004-07-22 Sankyo Company, Limited Isoquinolinone derivatives and their use as therapeutic agents
US20060270628A1 (en) 2003-04-29 2006-11-30 Jagattaran Das Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
WO2005113499A1 (ja) 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
WO2006003923A1 (ja) 2004-06-30 2006-01-12 Sankyo Company, Limited 置換ベンゼン化合物
GT200500208A (es) 2004-08-03 2006-03-02 Indazoles ùtiles para tratar enfermedades cardiovasculares
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US7213797B2 (en) 2005-05-20 2007-05-08 Garland Jerome Gaskins Deck board straightener
BRPI0612287A8 (pt) * 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
CN101248048B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 吡唑基lxr调节剂
ES2348332T3 (es) 2005-09-16 2010-12-02 Arrow Therapeutics Limited Derivados de bifenilo y su uso en el tratamiento de la hepatitis c.
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
EP1948636A2 (en) 2005-11-14 2008-07-30 Irm Llc Compounds and compositions as lxr modulators
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
CN101679297B (zh) * 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2009020683A2 (en) 2007-05-18 2009-02-12 Wyeth Quinazoline compounds
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
KR101171507B1 (ko) 2007-08-13 2012-08-07 에프. 호프만-라 로슈 아게 신규 피페라진 아마이드 유도체
EP2231617A1 (en) 2007-12-21 2010-09-29 Wyeth LLC Benzimidazole compounds
JP2011507900A (ja) 2007-12-21 2011-03-10 ワイス・エルエルシー イミダゾ［１，２−ａ］ピリジン化合物
US20120015988A1 (en) 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
US8063088B2 (en) 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
EP2352725A1 (en) 2008-11-07 2011-08-10 Wyeth LLC Quinoxaline-based lxr modulators
WO2010059627A1 (en) 2008-11-19 2010-05-27 Wyeth Llc Polar quinazolines as liver x receptors ( lxrs ) modulators
WO2010075203A1 (en) * 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
US20120058133A1 (en) 2009-02-19 2012-03-08 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
PE20120797A1 (es) 2009-05-28 2012-07-08 Exelisis Patent Company Llc Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
US20130137865A1 (en) 2010-08-11 2013-05-30 Taisho Pharmaceutical Co., Ltd. Heteroaryl-pyrazole derivative
CA2809830C (en) 2010-08-27 2019-09-10 Calcimedica, Inc. Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
CN102584705B (zh) * 2011-01-18 2015-05-13 中国中化股份有限公司 3-羟基-取代吡唑的制备方法
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
HUE040231T2 (hu) * 2012-03-02 2019-02-28 Ralexar Therapeutics Inc Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére
EP2882496B1 (en) 2012-08-13 2019-10-09 The Rockefeller University Treatment and diagnosis of melanoma
WO2014034584A1 (ja) 2012-08-27 2014-03-06 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、照明装置及び表示装置
JP5874679B2 (ja) 2013-04-25 2016-03-02 トヨタ自動車株式会社 燃料電池
LT3041835T (lt) 2013-09-04 2020-07-27 Ellora Therapeutics, Inc. Kepenų x receptoriaus (lxr) moduliatoriai
SG11201601644RA (en) 2013-09-04 2016-04-28 Alexar Therapeutics Inc Liver x receptor (lxr) modulators

Also Published As

Publication number Publication date
AU2014315280B2 (en) 2019-01-24
US20160221956A1 (en) 2016-08-04
MX2016002931A (es) 2016-07-26
CN110003108A (zh) 2019-07-12
US20230212127A1 (en) 2023-07-06
PT3041835T (pt) 2020-07-13
US10047055B2 (en) 2018-08-14
US20220106274A1 (en) 2022-04-07
US11034657B2 (en) 2021-06-15
PL3041835T3 (pl) 2020-10-19
HUE051094T2 (hu) 2021-03-01
CY1124057T1 (el) 2022-03-24
MX371343B (es) 2020-01-27
SI3041835T1 (sl) 2020-09-30
KR20160048996A (ko) 2016-05-04
EP3041835A1 (en) 2016-07-13
JP2016530296A (ja) 2016-09-29
CN105658636B (zh) 2019-05-14
US10246419B2 (en) 2019-04-02
EP3626712A2 (en) 2020-03-25
EP3626712A3 (en) 2020-04-15
HRP20201054T1 (hr) 2021-01-08
JP6821737B2 (ja) 2021-01-27
ES2804304T3 (es) 2021-02-05
SG11201601640SA (en) 2016-04-28
US20180346427A1 (en) 2018-12-06
DK3041835T3 (da) 2020-07-13
BR112016004904A2 (pt) 2017-08-01
US20220388963A1 (en) 2022-12-08
EP3041835B1 (en) 2020-04-08
CA2923175A1 (en) 2015-03-12
WO2015035015A1 (en) 2015-03-12
IL244418A0 (en) 2016-04-21
BR112016004904B1 (pt) 2023-01-24
IL244418B (en) 2019-11-28
CN105658636A (zh) 2016-06-08
JP2019147807A (ja) 2019-09-05
CA2923175C (en) 2022-07-26
AU2014315280A1 (en) 2016-03-24
US20210269406A1 (en) 2021-09-02
LT3041835T (lt) 2020-07-27
EP3041835A4 (en) 2017-04-26
NZ717688A (en) 2021-07-30
US20190169131A1 (en) 2019-06-06
KR102281803B1 (ko) 2021-07-28
RS60479B1 (sr) 2020-08-31
JP6806961B2 (ja) 2021-01-06

Similar Documents

Publication Publication Date Title
EA201990848A1 (ru) ЗАМЕЩЕННЫЕ 1H-ИМИДАЗО[4,5-b]ПИРИДИН-2(3H)-ОНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GLUN2B
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
BR112016025659A8 (pt) compostos, seus usos, e composições farmacêuticas para induzir condrogênese
BR112015021999A8 (pt) inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
EA201890245A1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
EA201491520A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
PH12019500949A1 (en) Ror-gamma modulators

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: RALEXAR THERAPEUTICS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 401/04 , C07D 409/14

Ipc: C07D 401/04 (2006.01), C07D 409/14 (2006.01), A61P

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: ELLORA THERAPEUTICS, INC. (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2014, OBSERVADAS AS CONDICOES LEGAIS